Watson Health Perspectives: 6 considerations for value-based contracting for medications

  1. How life sciences companies and payers will set the correct unit of value.
  2. Clarity about who will bear the administrative burden of documenting patient outcomes.
  3. Outcomes might unintentionally drive price increases.
  4. Value-based contracts could impact off-label utilization.
  5. How this information could affect quality indicators in the future.
  6. Addressing other regulatory issues
  7. such as Medicaid’s “best price” policy.
Notes: From a blog by Arti Bhavsar PharmD, Linda Elbers PharmD, and Katherine Haverty.

Source: Watson Health Perspectives/IBM, November 6, 2020 - https://www.ibm.com/blogs/watson-health/considerations-contracting-medications/

All HealthSprocket Lists